Monitor for additional selling by insiders, particularly from executive officers; while the sales are not large relative to market cap, the concentration in a single director may reflect personal liquidity needs rather than negative sentiment. Option exercises by executives could signal confidence in long-term stock performance.
Price Chart
Executive Summary
Krystal Biotech insiders executed a cluster of trades over the past week, including open-market sales totaling $4.4 million. CEO Krish S. Krishnan and President of R&D Suma Krishnan exercised stock options (non-cash), while Chief Accounting Officer Kathryn Romano sold $200,700 worth of shares and also exercised options. Director Daniel Janney sold over $4.4 million in three transactions, representing the bulk of the activity.
Key Financial Metrics
Key Facts
- Director Daniel Janney sold 15,233 shares in open-market transactions for $4.395 million over three days.
- CEO Krish S. Krishnan and President of R&D Suma Krishnan exercised options for 8,750 and 22,500 shares respectively (non-cash events).
- Chief Accounting Officer Kathryn Romano sold 750 shares for $200,700 and exercised 7,500 options (non-cash).
- Total open-market sales in the cluster: $4.4 million.
- Open-market sales represent ~0.058% of KRYS's $7.6B market cap — modest but not highly material.
Financial Impact
$4.4 million in open-market sales, primarily by director Daniel Janney
Risk Factors
- Perception of insider selling may weigh on sentiment, especially if followed by further divestitures.
- Option exercises increase share count slightly, leading to minor dilution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (7 trades, 7d window) | cluster-KRYS-1772580880774 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | Insider Cluster | $351.26 $336.68 | ▲ +4.15% | ▲ +3.03% | $322.28 (+8.25%) |
Aug 14, 2026 7w ago | 144 | $335.73 $341.72 | ▲ +1.78% | ▲ +2.97% | $322.28 (−4.01%) |
Aug 3, 2026 8w ago | 8-K | $312.57 $331.59 | ▲ +6.08% | ▲ +4.06% | $322.28 (+3.11%) |
Jul 23, 2026 10w ago | Press Release | $335.19 $366.85 | ▲ +9.45% | ▲ +9.07% | $322.28 (−3.85%) |
Jun 5, 2026 17w ago | Insider Cluster | $301.76 $324.75 | ▲ +7.62% | ▲ +5.51% | $322.28 (+6.80%) |
May 4, 2026 21w ago | Press Release | $286.95 $312.88 | ▲ +9.04% | ▲ +6.10% | $322.28 (+12.31%) |
Apr 21, 2026 23w ago | Press Release | $272.66 $269.27 | ▼ −1.24% | ▼ −2.33% | $322.28 (+18.20%) |
Apr 3, 2026 26w ago | DEFA14A | $261.80 $267.41 | ▲ +2.14% | ▼ −1.99% | $322.28 (+23.10%) |
Feb 27, 2026 31w ago | Insider Cluster | $275.64 $253.69 | ▼ −7.96% | ▼ −5.98% | $322.28 (+16.92%) |
Feb 27, 2026 31w ago | Insider Cluster | $275.64 $253.69 | ▼ −7.96% | ▼ −5.98% | $322.28 (+16.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access